| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 11 | 2024 | 765 | 1.760 |
Why?
|
| Influenza Vaccines | 8 | 2024 | 498 | 1.610 |
Why?
|
| Hospitalization | 23 | 2024 | 2167 | 1.260 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2024 | 214 | 0.930 |
Why?
|
| Intubation, Intratracheal | 8 | 2024 | 469 | 0.800 |
Why?
|
| Laryngoscopes | 4 | 2023 | 84 | 0.770 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2019 | 17 | 0.680 |
Why?
|
| Critical Illness | 7 | 2024 | 739 | 0.650 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 44 | 0.650 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 41 | 0.640 |
Why?
|
| Vaccination | 9 | 2024 | 1166 | 0.590 |
Why?
|
| Bronchoscopy | 5 | 2019 | 481 | 0.560 |
Why?
|
| Pneumonia | 2 | 2022 | 796 | 0.540 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 585 | 0.540 |
Why?
|
| Pleurisy | 1 | 2015 | 12 | 0.520 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 3 | 0.510 |
Why?
|
| Time | 1 | 2015 | 183 | 0.490 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 444 | 0.490 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 35 | 0.480 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 50 | 0.460 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 229 | 0.430 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2012 | 8 | 0.420 |
Why?
|
| Laryngoscopy | 3 | 2023 | 199 | 0.410 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2019 | 260 | 0.410 |
Why?
|
| Risk Assessment | 3 | 2015 | 6764 | 0.400 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 291 | 0.390 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 223 | 0.360 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2019 | 87 | 0.360 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 562 | 0.360 |
Why?
|
| Heart Arrest | 3 | 2024 | 382 | 0.360 |
Why?
|
| Shock | 2 | 2022 | 93 | 0.360 |
Why?
|
| Hypoxia | 2 | 2024 | 472 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 40 | 0.340 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 678 | 0.320 |
Why?
|
| Humans | 70 | 2024 | 270740 | 0.320 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 4372 | 0.310 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1894 | 0.310 |
Why?
|
| Adult | 38 | 2024 | 82040 | 0.310 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 136 | 0.290 |
Why?
|
| Pneumonectomy | 1 | 2012 | 862 | 0.280 |
Why?
|
| Seasons | 3 | 2024 | 337 | 0.270 |
Why?
|
| United States | 17 | 2024 | 15861 | 0.270 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 13 | 0.260 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 179 | 0.260 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 719 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 7783 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2024 | 6224 | 0.240 |
Why?
|
| Aged | 28 | 2024 | 73333 | 0.240 |
Why?
|
| Bias | 1 | 2024 | 216 | 0.230 |
Why?
|
| Middle Aged | 28 | 2024 | 90352 | 0.220 |
Why?
|
| Polysomnography | 3 | 2019 | 175 | 0.220 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 131 | 0.220 |
Why?
|
| Influenza A virus | 1 | 2024 | 166 | 0.210 |
Why?
|
| Hemoptysis | 2 | 2021 | 41 | 0.210 |
Why?
|
| Female | 32 | 2024 | 148940 | 0.210 |
Why?
|
| Respiratory Paralysis | 1 | 2001 | 9 | 0.200 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 15 | 0.200 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 4831 | 0.190 |
Why?
|
| Pulmonary Atelectasis | 1 | 2001 | 51 | 0.190 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 117 | 0.190 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 59 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2022 | 192 | 0.190 |
Why?
|
| Aneurysm | 1 | 2021 | 90 | 0.180 |
Why?
|
| Male | 25 | 2024 | 128315 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 128 | 0.180 |
Why?
|
| Hypotension | 1 | 2022 | 232 | 0.180 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 372 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2024 | 347 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2022 | 209 | 0.170 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2019 | 82 | 0.170 |
Why?
|
| Mediastinitis | 2 | 2017 | 22 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 2021 | 140 | 0.170 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 576 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 163 | 0.160 |
Why?
|
| Azithromycin | 1 | 2019 | 79 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 408 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2023 | 6390 | 0.160 |
Why?
|
| Cough | 1 | 2019 | 125 | 0.160 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 1379 | 0.150 |
Why?
|
| Home Care Services | 1 | 2018 | 99 | 0.150 |
Why?
|
| Adolescent | 9 | 2024 | 32767 | 0.150 |
Why?
|
| Hospital Mortality | 4 | 2024 | 1234 | 0.140 |
Why?
|
| Long-Term Care | 1 | 2017 | 85 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2019 | 822 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2002 | 755 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 72 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 360 | 0.130 |
Why?
|
| Fever | 1 | 2019 | 521 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2017 | 138 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 166 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 689 | 0.130 |
Why?
|
| Carmine | 1 | 1995 | 1 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 499 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2021 | 1567 | 0.130 |
Why?
|
| Parasitic Diseases | 1 | 1996 | 66 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 206 | 0.120 |
Why?
|
| Oxygen | 3 | 2024 | 791 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 1996 | 229 | 0.120 |
Why?
|
| Leiomyoma | 1 | 1996 | 161 | 0.120 |
Why?
|
| Legionella | 1 | 2014 | 18 | 0.120 |
Why?
|
| Bacteremia | 1 | 2020 | 721 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 286 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 175 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 3187 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 1060 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 1996 | 251 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2024 | 13414 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2017 | 738 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 417 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 1995 | 235 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 42 | 0.110 |
Why?
|
| Logistic Models | 2 | 2021 | 3444 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 572 | 0.100 |
Why?
|
| Influenza B virus | 2 | 2024 | 97 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 334 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 30998 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 442 | 0.100 |
Why?
|
| Young Adult | 7 | 2024 | 22251 | 0.100 |
Why?
|
| Video Recording | 2 | 2023 | 281 | 0.090 |
Why?
|
| Trachea | 2 | 2023 | 298 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 5101 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 2311 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 558 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2330 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 1090 | 0.080 |
Why?
|
| Lung | 3 | 2014 | 3298 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3891 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3476 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 1063 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 4960 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2020 | 39890 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1452 | 0.070 |
Why?
|
| Sleep | 2 | 2019 | 442 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2024 | 9470 | 0.060 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 35 | 0.060 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1255 | 0.060 |
Why?
|
| Biopsy | 1 | 2012 | 3484 | 0.060 |
Why?
|
| Masks | 1 | 2024 | 59 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2023 | 850 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 78 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2650 | 0.050 |
Why?
|
| Bronchial Diseases | 1 | 2003 | 46 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 172 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 12 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 33 | 0.050 |
Why?
|
| Prognosis | 3 | 2019 | 22505 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 359 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2001 | 4 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2004 | 502 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 73 | 0.050 |
Why?
|
| Heart Septum | 1 | 2001 | 60 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 123 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 115 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 166 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 399 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 485 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 484 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 15218 | 0.050 |
Why?
|
| Subclavian Artery | 1 | 2021 | 79 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 213 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 60 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2023 | 730 | 0.040 |
Why?
|
| Enterococcus | 1 | 2020 | 61 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 433 | 0.040 |
Why?
|
| Diaphragm | 1 | 2001 | 187 | 0.040 |
Why?
|
| Vincristine | 1 | 2004 | 1583 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 337 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 350 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 294 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 12033 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 884 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 3245 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 477 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1407 | 0.040 |
Why?
|
| Heart Atria | 1 | 2001 | 354 | 0.040 |
Why?
|
| Prevalence | 2 | 2023 | 3404 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 796 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2003 | 383 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 292 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6449 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1158 | 0.040 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 41 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 669 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 312 | 0.040 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 12 | 0.040 |
Why?
|
| Fallopian Tube Diseases | 1 | 1997 | 19 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 49 | 0.040 |
Why?
|
| Ileal Diseases | 1 | 1997 | 27 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2004 | 3145 | 0.040 |
Why?
|
| Intestinal Fistula | 1 | 1997 | 48 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2022 | 1824 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 57 | 0.030 |
Why?
|
| Fistula | 1 | 1997 | 77 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2580 | 0.030 |
Why?
|
| Critical Care | 1 | 2002 | 796 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 613 | 0.030 |
Why?
|
| Stents | 2 | 2017 | 999 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 252 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 2007 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 404 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 462 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 55 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 231 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1301 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 372 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 855 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 233 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 146 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1610 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 445 | 0.030 |
Why?
|
| Sarcoma | 1 | 2004 | 1839 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 411 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 325 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2017 | 33737 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 964 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 5824 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2518 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2353 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 705 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 14012 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2828 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 3409 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6867 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 1903 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 61956 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6177 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 5681 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 13006 | 0.020 |
Why?
|
| Ohio | 1 | 2006 | 117 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2006 | 30 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 354 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 7655 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2006 | 412 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 495 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 127 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 16689 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2006 | 447 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2004 | 9292 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 209 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 7914 | 0.010 |
Why?
|
| Risk Factors | 2 | 2006 | 17888 | 0.010 |
Why?
|
| Adnexal Diseases | 1 | 1997 | 28 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 4000 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 1432 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2400 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 1174 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 4328 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 4963 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 9039 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2001 | 10400 | 0.000 |
Why?
|